New drug therapies for advanced renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 7, Issue 1, 2007, Pages 57-71

  Harrison, Michelle L ^a   Montes, Ana ^a   Gore, Martin E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Anti angiogenic; Bevacizumab; Immunotherapy; Inhibitors; Metastatic; Renal cell carcinoma; Sorafenib; Sunitinib; Temsirolimus; Tyrosine inase

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA INTERFERON; AXITINIB; BCG VACCINE; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IMATINIB; INFLIXIMAB; INTERLEUKIN 2; IXABEPILONE; LAPATINIB; LENALIDOMIDE; MEDROXYPROGESTERONE ACETATE; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADJUVANT THERAPY; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ASTHENIA; BLISTER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; HAND FOOT SYNDROME; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY CARCINOMA; LIMB PAIN; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHLEBITIS; PNEUMONIA; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS;

EID: 33846504851     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.1.57     Document Type: Review

References (115)

1. Edwards BK, Brown ML, Wingo PA et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl Cancer Inst. 97, 1407-1427 (2005).
2. Jemal A, Siegel R, Ward E et al. Cancer statistics 2006. CA Cancer J. Clin. 56, 106-130 (2006).
3. Gettman MT, Blute ML, Sports B et al. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 91, 354-361 (2001).
4. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90 (1994).
5. Kondo K, Yao M, Yoshida M et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34, 58-68 (2002).
6. Pause A, Lee S, Worrell RA et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl Acad. Sci. USA 94, 2156-2161 (1997).
7. Lonergan KM, Iliopoulos O, Ohh M et al. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell Biol. 18, 732-741 (1998).
8. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor-protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999).
9. Turner KJ, Moore JW, Jones A et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 62, 2957-2961 (2002).
10. Kourembanas S, Hannan RL and Faller DV. Oxygen tension regulates the expression of platelet-derived growth factor-B chain gene in human epithelial cells. J. Clin. Invest. 86, 670-674 (1990).
11. Gunaratnam L, Morley M, Franovic A et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278, 44966-44974 (2003).
12. Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J. Pathol. 183, 131-133 (1997).
13. De Peralta-Venturina M, Moch H, Amin M et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am. J. Surg. Pathol 25, 275-284 (2001).
14. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649-1657 (2001).
15. Kjaer M, Iversen P, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int. J. Radiat. Oncol. Biol. Phys. 5, 665-672 (1987).
16. Pizzocaro G, Piva L, Di Frinzo G et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 19, 425-431 (2001).
17. Messing EM, Manota J, Wilding G et al. Phase III study of interferon α-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol. 21, 1214-1222 (2003).
18. Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol. 2, 3133-3140 (2003).
19. Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2- and interferon-α2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br. J. Cancer 92, 843-846 (2005).
20. Galligioni E, Quaia M, Merlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77, 2560-2566 (1996).
21. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363, 594-599 (2004).
22. Yogoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol. 22, 42-60 (1995).
23. Amato RJ. Chemotherapy for renal cell carcinoma. Semin. Oncol. 27, 177-186 (2000).
24. Lee CP, Patel PM, Selby PJ et al. Randomized Phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 898-903 (2006).
25. Medical Research Council Renal Cancer Collaborators. Interferon-S and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353, 14-17 (1999).
26. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J. Urol. 163, 408-417 (2000).
27. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999).
28. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann. Oncol. 13, 1460-1468 (2002).
29. Negrier S, Perol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 4511).
30. Pythonen S, Salminen E, Ruutu M et al, Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17, 2859-2867 (1999).
31. Fyfe G, Faber RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
32. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
33. McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
34. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338, 1272-1279 (1998).
35. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
36. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11, 3714-3721 (2005).
37. Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon α-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 2972-2980 (2000).
38. Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2- and interfiron α-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).J. Clin. Oncol. 22, 1188-1194 (2005).
39. Aass N, De Mulder PH, Miskisch GH et al Randomized Phase II/III trial of interferon α-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J. Clin. Oncol. 23, 4172-4178 (2005).
40. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med 345, 1655-1659 (2001).
41. Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966-970 (2001).
42. Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071-1076 (2004).
43. Slaton JW, Perrotte P, Balbay MD. Reassessment of the selection criteria for cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol. 163(79), S4 (2000).
44. Han KR, Pantuck AJ, Bui MH et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma Urology 61, 314-319 (2003).
45. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
46. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
47. Ratain MJ, Eisen T, Sadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006).
48. Escudier R, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 4510).
49. Eisen T, Bukowski RM, Stadhler C et al. Randomized Phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 4524).
50. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003).
51. O'Farell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605 (2003).
52. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Cin. Oncol. 24, 16-24 (2006).
53. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006).
54. Motzer RJ, Hutson TE, Tomczak P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-α (IFN-α) as first-line systemic therapy for patients with metastatic renal carcinoma (mRCC). Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract LBA3).
55. De Mulder PH, Roigas J, Gillessen S et al. A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 4529).
56. Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 22, 7004-7014 (2002).
57. Vignot S, Faivre S, Aguirre D et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 16, 525-537 (2005).
58. Brenner W, Farber G, Herget T et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int. J. Cancer 99, 53-57 (2002).
59. Hara S, Oya M, Mizuno R et al. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol. 16, 928-933 (2005).
60. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22, 909-918 (2004).
61. Hudes G, Carducci M, Tomczak P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination or TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract LBA4).
62. Tabernero J Rojo F, Berris, et al. A Phase I study with tumor molecular pharmacodynamic evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD 001) in patients with advanced solid tumors. Proc. Am Soc. Clin. Oncol. 23, S16 (2005) (Abstract 3007).
63. Amato RJ, Misellati A, Khan M et al. A phase II trial of RAD 001 in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Absract 4530).
64. Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
65. Ravaud A, Gardner J, Hawkins H et al. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a Phase III trial in advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) Obstract 4502).
66. Mendelshon J and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 14, 2787-2799 (2003).
67. Vuky J, Isacson C, Fotoohi M et al. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Invest. New Drugs 24, 85-88 (2006).
68. Dawson NA, Guo C, Zak R et al. A Phase II trial of gefitinib, (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin. Can. Res. 10, 7812-7819 (2004).
69. Drucker B, Bacik J, Ginsberg M et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest. New Drugs 21, 341-345 (2003).
70. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4, 565-573 (2003).
71. Maisey NR, Hall K, Lee C et al. Infliximab: A phase II trial of the tumour necrosis factor (TNFα) monoclonal antibody in patients with advanced renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. 22, S14 (2004) (Abstract 4514).
72. Liu Z, Smyth FE, Renner C et al. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 51, 171-177 (2002).
73. Bleumer I, Knuth A, Oosterwijk E et al. A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 90, 985-990 (2004).
74. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997).
75. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
76. Hainsworth JD, Sosman JA, Spigel DR et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23, 7889-7896 (2005).
77. Bukowski RM, Kabbinavar F, Figlin RA et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC) Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 4523).
78. Thompson DS, Greco FA, Spigel DR et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advance renal cell carcinoma: Update of a multicenter Phase II trial. Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 4594).
79. Gill GN, Kawamoto T, Cochet C et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259, 7755-7760 (1984).
80. Yang XD, Jia XC, Corvalan JRF et al. Development of ABX-EGF, a fully human and-EGF receptor monoclonal antibody for cancer therapy. Crit. Rev. Oncol. Hematol. 38, 17-23 (2001).
81. Motzer RJ, Amato R, Todd M et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21, 99-101 (2003).
82. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22, 3003-3015 (2004).
83. Kuenen BC, Tabernero J, Baselga J et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 9, 1648-1655 (2003).
84. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG'h013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23, 5474-5483 (2005).
85. Rini B, Rixe OR, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 4509).
86. Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171. a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 3002).
87. Van Cruijsen H, Voest EE, Van Herpen CM et al. Phase I clinical evaluation of AZD2171 in combination with gefitinib (Iressa), in patients with advanced tumors. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 3030).
88. Martinelli E, Takimoto CT, Van Oosterom A et al. AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: preliminary phase 1 results. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 3039).
89. Sanchez-Ortiz R, Tamboli P, Lozano ML et al. Adjuvant thalidomide improves disease specific survival for patients with renal cell carcinoma at high risk for relapse following surgery. Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 14586).
90. Gordon MS, Manola J, Fairclough D et al. Low dose interferon-α2b + thalidomide in patients with previously untreated renal cell cancer. Improvement in progression-free survival but not quality of life or overall survival. A Phase III study of the Eastern Cooperative Oncology Group (E2898). Proc. Am. Soc. Clin. Oncol. 22, S14 (2004) (Abstract 4516).
91. Schrader AJ, Heidenreich A, Hegele A et al. application of thalidomide/ interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma. Anticancer Drugs 16, 581-585 (2005).
92. Olencki T, Malhi S, Mekhail T et al. Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma. Invest. New Drugs 24, 321-326 (2006).
93. Amato RJ, Morgan M and Rawat A. Phase I/II study of thalidomide in combination with Interleukin-2 in patients with metastatic renal cell carcinoma. Cancer 106, 1498-1506 (2006).
94. Choueiri TK, Dreicer R, Rini BI et al. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107, 2609-2616 (2006).
95. Zhuang SH, Menefee M, Kotz H et al. A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. Proc. Am. Soc. Clin. Oncol. 22, S14 (2004) (Abstract 4450).
96. Posadas EM, Undevia S, Colevas D et al, A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol 24, S18 (2006) (Abstract 14646).
97. Cobb PW, July F, Venner P et al. An uncontrolled phase II multi-center trial evaluating anti-tumor efficacy and safety of BAY 59-8862 in patients with advanced renal cell cancer. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 1640).
98. Stadler WM, Halabi H., Ernstoff MS et al. A phase II study of gemcitabine and capecitabine in patients with metastatic renal cell cancer: A report of Cancer and Leukemia Group B 90008. Proc. Am. Soc. Clin. Oncol. 22, S14 (2004) (Abstract 4515).
99. Tannir NM, Jonasch E, McMichael C et al. A Phase II Trial of Gemcitabine plus Capecitabine in Patients with Advanced Renal Cell Cancer Previously Treated with Immunotherapy. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 4598).
100. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343, 750-758 (2000).
101. Artz AS, Van Besien K, Zimmerman T et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant 35, 253-260 (2005).
102. Barkholt L, Bregni M, Romberger M et al, Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann. Oncol. 17, 1134-1140 (2006).
103. Amato RJ. Vaccine therapy for renal cell carcinoma. Rev Urol. 5, 65-71 (2003).
104. Berntsen A, Geertsen PF, and Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur. Urol. 50, 34-43 (2006).
105. Holtl L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer 8, 3369-3376 (2002).
106. Wierecky J, Muller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic Cancer Res. 66, 5910-5918 (2006).
107. Amato RJ, Murray L, Wood et al. Active specific immunotherapy in patients with renal cell carcinoma using autologous tumour derived heat-shock protein-peptide complex-96 (HSPP-96) vaccine. Proc. Am. Soc. Clin. Oncol. 18 (1999) (Abstract 332).
108. Assikis VJ, Dagliani D, Pagliaro L et al. A multicenter randomized study of adjuvant heat-shock protein-peptide complex-96 (HSPP-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 1552).
109. Wood CG, Escudier B, Gorelov S et al. A multicenter randomized study of adjuvant heat-shock protein peptide-complex 96 (HSPPC-96) vaccine in patients with high-risk of recurrence after nephrectomy for renal cell carcinoma - a preliminary report. Proc. Am. Soc. Clin. Oncol. 22 (2004) (Abstract 2618).
110. Yang JC, Beck KE, Blansfield JA et al. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). Proc. Am. Soc. Clin. Oncol. 23 S16 (2005) (Abstract 2501).
111. An J, Sun Y, Fisher M et al. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-κB dependent. Mol. Cancer Ther. 3, 727-736 (2004).
112. Davis NB, Taber DA, Ansari RH et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortiam study. J. Clin. Oncol. 22, 115-119 (2004).
113. Kondagunta GV, Ducker B, Schwartz L et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol, 22, 3720-3725 (2004).
114. Ronnen EA, Kondagunta GV and Morzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J. Clin. Oncol. 24, 14 (2006).
115. Zalcberg JR, Verweij J, Casali PG et al. Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur. J. Cancer 41, 1751-1757 (2005).